Virksomhedens formål er at skabe avanceret software med henblik på udvikling af nye immunterapier og vacciner.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 48.1 mio. | -51.5 mio. | 180.5 mio. | 108.3 mio. | 45 | |
CVR: 31762863
Secondary names: NOVVAC A/S, EVAXION BIOTECH A/S
Previous names: NOVVAC ApS, EVAXION BIOTECH ApS, EVAXION BIOTECH A/S
Compared to 999 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Jens Bitsch-Nørhave joined the board
Helen Katrina Tayton-Martin left the board
Helen Katrina Tayton-Martin joined as ADM. DIR.
Birgitte Rønø left as ADM. DIR.
Birgitte Rønø joined as ADM. DIR.
Christian Kanstrup left as ADM. DIR.
Evaxion A/S is currently facing significant financial challenges, as evidenced by its declining profitability and fluctuating equity position. In 2025, the company reported a revenue of 48.1 million DKK but incurred a loss of 51.5 million DKK, following a trend of increasing losses from previous years, including a staggering loss of 152.4 million DKK in 2023. While equity improved to 108.3 million DKK in 2025, it had previously dipped to negative figures, raising concerns about financial stability. The company operates in the research and experimental development sector, where it must navigate these financial hurdles to strengthen its market position and achieve sustainable growth.
AI-generated summary
Companies in the same industry and area
companydata.dk